castle biosciences inc - CSTL
CSTL
Close Chg Chg %
27.57 0.60 2.18%
Closed Market
28.17
+0.60 (2.18%)
Volume: 563.10K
Last Updated:
Mar 4, 2026, 4:00 PM EDT
Company Overview: castle biosciences inc - CSTL
CSTL Key Data
| Open $27.74 | Day Range 27.40 - 28.60 |
| 52 Week Range 14.59 - 44.28 | Market Cap $819.69M |
| Shares Outstanding 29.73M | Public Float 28.94M |
| Beta 1.09 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.84 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 512.81K |
CSTL Performance
| 1 Week | -4.73% | ||
| 1 Month | -13.98% | ||
| 3 Months | -27.10% | ||
| 1 Year | 39.39% | ||
| 5 Years | -59.16% |
CSTL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About castle biosciences inc - CSTL
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
CSTL At a Glance
Castle Biosciences, Inc.
505 South Friendswood Drive
Friendswood, Texas 77546
| Phone | 1-866-788-9007 | Revenue | 344.23M | |
| Industry | Medical Specialties | Net Income | -24,158,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 3.662% | |
| Fiscal Year-end | 12 / 2026 | Employees | 883 | |
| View SEC Filings |
CSTL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.276 |
| Price to Book Ratio | 2.452 |
| Price to Cash Flow Ratio | 17.52 |
| Enterprise Value to EBITDA | -424.26 |
| Enterprise Value to Sales | 2.513 |
| Total Debt to Enterprise Value | 0.043 |
CSTL Efficiency
| Revenue/Employee | 389,840.317 |
| Income Per Employee | -27,359.003 |
| Receivables Turnover | 7.935 |
| Total Asset Turnover | 0.592 |
CSTL Liquidity
| Current Ratio | 5.258 |
| Quick Ratio | 5.109 |
| Cash Ratio | 4.361 |
CSTL Profitability
| Gross Margin | 68.66 |
| Operating Margin | -12.436 |
| Pretax Margin | -8.574 |
| Net Margin | -7.018 |
| Return on Assets | -4.154 |
| Return on Equity | -5.214 |
| Return on Total Capital | -4.757 |
| Return on Invested Capital | -4.899 |
CSTL Capital Structure
| Total Debt to Total Equity | 7.861 |
| Total Debt to Total Capital | 7.288 |
| Total Debt to Total Assets | 6.076 |
| Long-Term Debt to Equity | 7.469 |
| Long-Term Debt to Total Capital | 6.925 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Castle Biosciences Inc - CSTL
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 137.04M | 219.79M | 332.07M | 344.23M | |
Sales Growth
| +45.65% | +60.38% | +51.09% | +3.66% | |
Cost of Goods Sold (COGS) incl D&A
| 41.68M | 55.55M | 73.25M | 107.88M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 10.54M | 12.33M | 16.00M | 40.77M | |
Depreciation
| 2.28M | 3.32M | 4.89M | 5.93M | |
Amortization of Intangibles
| 8.27M | 9.01M | 11.11M | 34.84M | |
COGS Growth
| +122.27% | +33.29% | +31.86% | +47.28% | |
Gross Income
| 95.36M | 164.23M | 258.82M | 236.35M | |
Gross Income Growth
| +26.58% | +72.22% | +57.59% | -8.68% | |
Gross Profit Margin
| +69.59% | +74.72% | +77.94% | +68.66% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 186.50M | 232.21M | 250.15M | 279.16M | |
Research & Development
| 44.57M | 53.29M | 51.69M | 51.49M | |
Other SG&A
| 141.94M | 178.92M | 198.46M | 227.66M | |
SGA Growth
| +61.59% | +24.51% | +7.72% | +11.60% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (18.29M) | (555.00K) | (982.00K) | |
EBIT after Unusual Expense
| (72.85M) | (67.98M) | 9.22M | (41.83M) | |
Non Operating Income/Expense
| 3.97M | 10.62M | 12.92M | 12.40M | |
Non-Operating Interest Income
| 3.97M | 10.62M | 12.92M | 11.77M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 17.00K | 11.00K | 577.00K | 86.00K | |
Interest Expense Growth
| +1,600.00% | -35.29% | +5,145.45% | -85.10% | |
Gross Interest Expense
| 17.00K | 11.00K | 577.00K | 86.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (68.90M) | (57.37M) | 21.56M | (29.51M) | |
Pretax Income Growth
| -72.21% | +16.75% | +137.59% | -236.87% | |
Pretax Margin
| -50.28% | -26.10% | +6.49% | -8.57% | |
Income Tax
| (1.77M) | 101.00K | 3.32M | (5.36M) | |
Income Tax - Current - Domestic
| 111.00K | 324.00K | 1.92M | 872.00K | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (1.88M) | (223.00K) | 1.40M | (6.23M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (67.14M) | (57.47M) | 18.25M | (24.16M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (67.14M) | (57.47M) | 18.25M | (24.16M) | |
Net Income Growth
| -114.55% | +14.41% | +131.75% | -232.41% | |
Net Margin Growth
| -48.99% | -26.15% | +5.49% | -7.02% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (67.14M) | (57.47M) | 18.25M | (24.16M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (67.14M) | (57.47M) | 18.25M | (24.16M) | |
EPS (Basic)
| -2.5769 | -2.1441 | 0.6569 | -0.8334 | |
EPS (Basic) Growth
| -107.00% | +16.80% | +130.64% | -226.87% | |
Basic Shares Outstanding
| 26.05M | 26.80M | 27.78M | 28.99M | |
EPS (Diluted)
| -2.5769 | -2.1441 | 0.6236 | -0.8334 | |
EPS (Diluted) Growth
| -107.00% | +16.80% | +129.08% | -233.64% | |
Diluted Shares Outstanding
| 26.05M | 26.80M | 29.25M | 28.99M | |
EBITDA
| (80.60M) | (55.65M) | 24.67M | (2.04M) | |
EBITDA Growth
| -119.78% | +30.96% | +144.33% | -108.27% | |
EBITDA Margin
| -58.81% | -25.32% | +7.43% | -0.59% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 48.50 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.49 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -1.175 | |
| Last Quarter’s Earnings | -0.08 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.83 | Next Fiscal Year Estimate | -0.544 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 8 | 8 | 8 |
| Mean Estimate | -0.49 | -0.31 | -1.18 | -0.54 |
| High Estimates | -0.29 | -0.24 | -0.79 | -0.18 |
| Low Estimate | -0.58 | -0.38 | -1.43 | -0.85 |
| Coefficient of Variance | -23.24 | -18.78 | -22.70 | -51.49 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 7 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Castle Biosciences Inc - CSTL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Castle Biosciences Inc - CSTL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 23, 2026 | Derek J. Maetzold Pres. & Chief Exec. Officer; Director | 87,715 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $40.01 per share | 3,509,477.15 |
| Aug 13, 2025 | Derek J. Maetzold Pres. & Chief Exec. Officer; Director | 112,702 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.36 per share | 2,181,910.72 |
| Aug 13, 2025 | Tobin W. Juvenal Chief Commercial Officer | 84,527 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.36 per share | 1,636,442.72 |
| Aug 13, 2025 | Tobin W. Juvenal Chief Commercial Officer | 88,821 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 13, 2025 | Tobin W. Juvenal Chief Commercial Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 13, 2025 | Franklin Michael Stokes Chief Financial Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 13, 2025 | Franklin Michael Stokes Chief Financial Officer | 48,716 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.36 per share | 943,141.76 |
| Aug 13, 2025 | Franklin Michael Stokes Chief Financial Officer | 53,072 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 13, 2025 | Kristen M. Oelschlager Chief Operating Officer | 174,604 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 13, 2025 | Derek J. Maetzold Pres. & Chief Exec. Officer; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 13, 2025 | Kristen M. Oelschlager Chief Operating Officer | 171,800 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.36 per share | 3,326,048.00 |
| Aug 13, 2025 | Kristen M. Oelschlager Chief Operating Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 12, 2025 | Derek J. Maetzold Pres. & Chief Exec. Officer; Director | 4,773 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.74 per share | 98,992.02 |
| Mar 12, 2025 | Derek J. Maetzold Pres. & Chief Exec. Officer; Director | 4,770 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.74 per share | 98,929.80 |
| Mar 12, 2025 | Derek J. Maetzold Pres. & Chief Exec. Officer; Director | 4,770 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.74 per share | 98,929.80 |
| Mar 12, 2025 | Derek J. Maetzold Pres. & Chief Exec. Officer; Director | 67,042 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.74 per share | 1,390,451.08 |
| Mar 12, 2025 | Derek J. Maetzold Pres. & Chief Exec. Officer; Director | 80,465 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.74 per share | 1,668,844.10 |
| Mar 12, 2025 | Derek J. Maetzold Pres. & Chief Exec. Officer; Director | 4,785 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.05 per share | 95,939.25 |
| Mar 12, 2025 | Derek J. Maetzold Pres. & Chief Exec. Officer; Director | 4,785 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.05 per share | 95,939.25 |
| Mar 12, 2025 | Derek J. Maetzold Pres. & Chief Exec. Officer; Director | 57,265 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.05 per share | 1,148,163.25 |